Bisht M, Bist S S, Dhasmana D C
Department of Pharmacology, Himalayan Institute of Medical Sciences, HIHT University Jolly grant, Doiwala, Dehradun, Uttarakhand, India.
Indian J Cancer. 2010 Oct-Dec;47(4):443-51. doi: 10.4103/0019-509X.73559.
Over the past few decades, considerable success has been achieved in the field of cancer treatment with biological response modifiers (BRM), which are agents that improve the body's ability to fight cancer by immunostimulation. Biological agents, such as interferons and interleukins, provide nonspecific active immunity, whereas the monoclonal antibodies provide passive immunity. Apart from this, other biological agents, such as antiangiogenic agents, matrix metalloprotease inhibitors, tyrosine kinase inhibitors, and tumor vaccines, are also increasingly being used in cancer treatment. Hematopoietic factors, such as granulocyte colony-stimulating factor, are used to increase the general immunity and prevent opportunistic infection. BRM are basically used alone or as adjuvants to cancer chemotherapeutic agents. This review sheds light on the current use and the future development of cancer immunotherapy. Search strategy included Pubmed, using the terms "Biological response modifiers in cancer" citations relevant to the topic were screened.
在过去几十年中，生物反应调节剂（BRM）在癌症治疗领域取得了相当大的成功，这些制剂通过免疫刺激提高机体对抗癌症的能力。生物制剂，如干扰素和白细胞介素，提供非特异性主动免疫，而单克隆抗体提供被动免疫。除此之外，其他生物制剂，如抗血管生成剂、基质金属蛋白酶抑制剂、酪氨酸激酶抑制剂和肿瘤疫苗，也越来越多地用于癌症治疗。造血因子，如粒细胞集落刺激因子，用于增强全身免疫力并预防机会性感染。BRM基本上单独使用或作为癌症化疗药物的佐剂。本综述阐明了癌症免疫疗法的当前应用和未来发展。检索策略包括使用“癌症中的生物反应调节剂”这一术语在PubMed上进行检索，筛选与该主题相关的文献。
